FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Vaccines Technologies, Celldex ink deal


Boston-based Vaccine Technologies (VTI) has inked a license and development agreement with Celldex Therapeutics. VTI will have exclusive licensing rights to Celldex's CholeraGarde and ETEC vaccine programs. The deal includes upront fees, milestone payments and worldwide royalties on net sales. Further financial details were not disclosed.

VTI will continue to develop CholeraGarde and ETEC in conjunction with Celldex's current partners, the International Vaccine Institute and the National Institute of Allergy and Infectious Diseases. CholeraGarde is currently in Phase II studies in Bangladesh under IVI, with plans underway to commence additional studies in India and Thailand this year. NIAID is currently conducting a Phase I study on ETEC for enterotoxigenic E.coli and cholera at the Cincinnati Children's Hospital Medical Center

"VTI has several initiatives underway including vaccines targeting hepatitis and influenza," Dr. Yichen Lu, President and CEO of VTI said in a statement. "Licensing of the CholeraGarde and ETEC vaccine programs is complementary and consistent with our goal to be a highly competitive vaccine research and development center and manufacturer."

- read the joint release

Related Articles:
Celldex inks tech deal to advance cancer vaccines
Avant, Celldex merge in $115M stock deal

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Vaccine   Celldex Therapeutics   Vaccine Technologies  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.